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Amphiphilic block co-polymers composed of poly(ethylene
glycol)-co-poly(lactide)-co-poly(2-((tert-butoxycarbonyl)amino)-3-propyl
carbonate) (PEG-pLA-pTBPC) are synthesized in monomer ratios and
arrangements to enable assembly into nanoparticles with different sizes and
architectures. These materials are based on components in clinical use, or
known to be biodegradable, and retain the same fundamental chemistry
across “AB” and “BAB” block architectures. In MCF7 and MDA-MB-231 breast
cancer cells, nanoparticles of <100 nm are internalized most rapidly, by both
clathrin- and caveolin-mediated pathways. In THP-1 cells, polymer
architecture and length of the hydrophilic block is the most important factor
in the rate of internalization. The organ distributions of systemically injected
nanoparticles in healthy mice indicate highest accumulation of the
BAB-blocks in lungs and liver and the lowest accumulation in these organs of
a methoxyPEG5000-pLA-pTBPC polymer. Conjugation of doxorubicin via a
serum-stable urea linker to the carbonate regions of PEG5000-pLA-pTBPC
generates self-assembling nanoparticles which are more cytotoxic in 2D, and
penetrate further in 3D spheroids of triple negative breast cancer cells, than
the free drug. In an aggressive orthotopic triple negative breast cancer mouse
model, the methoxyPEG5000-pLA-pTBPC is of similar potency to free
doxorubicin but with no evidence of adverse effects in terms of body weight.
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1. Introduction
Polymer pro-drugs offer much promise for
drug delivery, owing to the ability to tune
the macromolecular structures for solubil-
ity and stability in biological fluids, and to
encode for drug release in disease-specific
environments.[1] In addition, the wide va-
riety of synthetic routes available for con-
structing polymers is allowing materials
with highly defined structures, architec-
tures and release mechanisms to be formed
from easily accessible precursors.[2] Accord-
ingly, it is now possible to construct new
materials with a large range of physico-
chemical properties and, of significant im-
portance, from building blocks which are
either already in clinical use,[3] or which
have relatively low barriers to translation.[4]
However, for diseases including many can-
cers, there remain multiple unknowns con-
cerning how such new materials might
overcome the key barriers to drug delivery,
namely, the ability to concentrate a thera-
peutic agent in a target site in sufficient
dose and for sufficient time to afford an effi-
cacious response. The potential advantages
of polymer pro-drugs are that they can be
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designed to release drugs either at a controlled rate in plasma
to ensure drug concentrations remain in the therapeutic win-
dow, or they can be encoded with functionality to ensure that re-
lease only occurs in the disease site.[5] While there have been suc-
cesses with both approaches,[6] there are still significant potential
drawbacks.[7] For example, in the case of sustained drug release
formulations, high concentrations of long-circulating polymer
pro-drugs may be needed to maintain the plasma concentration
of the drug in the therapeutic range. In delivery systems designed
for site-specific release, the concentration of pro-drugs that reach,
for example, tumors, is well-documented as being low,[8] even
though this dose may still be much higher than that achieved
by many conventional systemically administered drugs.
In order to address both the above questions, we, and oth-
ers, have synthesized polymers which enable sustained release
in the bloodstream,[9] and also which can incur site-specific
or externally triggered in situ response.[10] We have also been
interested in exploring how polymer conformation and archi-
tecture alter these and other factors important in delivery, that
is, transport in the body, and in crossing tissue, cellular and in-
tracellular barriers. In particular, we are focusing on how poly-
mer and nanoparticle architecture affect the accessibility of linker
functionality to biological reagents or conditions,[11] and hence
how drug release and in vivo efficacy might be controlled both
for the “sustained release” types of carriers, and for the “site-
specific release” delivery systems. Here we report the evaluation
of polymer pro-drugs with the same fundamental chemistries
but with three variants of block structures and architectures, and
with functionality to attach the well-established anti-cancer drug
doxorubicin to the polymer backbone by a serum-stable urea
linker. The polymers were based on the poly(ethylene glycol)-co-
poly(lactide) class of co-polymermicelles, which have entered hu-
man clinical use[12] but with the hydrophobic block consisting of
poly(lactide)-co-poly(2-((tert-butoxycarbonyl)amino)-3-propyl car-
bonate), forming polymers we abbreviate as PEG-pLA-pTBPC.
Both poly(lactide) and poly(carbonate) polymers are known to be
biodegradable, albeit over different time periods, and the pres-
ence of the protected side-chain amine in the poly(carbonate) re-
gions allowed us access to further functionality, including drug
conjugation, via post-polymerization modification reactions.[13]
We have studied the behavior of these polymers to assemble into
nanoparticles suitable for systemic injection, and have investi-
gated their cytotoxicity in 2D and 3D cell cultures and in vivo. Our
specific emphasis for these studies was triple negative breast can-
cer (TNBC), as this disease is currently addressed poorly with cur-
rent therapies.[14] A number of innovative TNBC formulations
and nanosystems have recently been developed, often withmulti-
modal functionality.[15] In our case, we suggest that TNBCs in
particular might be targeted effectively with highly toxic payloads
which are released only in the tumor regions owing to increased
activity of proteolytic enzymes, such as plasmin, which have been
shown to act also on urea-type pro-drugs in breast cancer.[16] We
demonstrate that the polymer-doxorubicin pro-drugs are retained
in the body of healthy mice for a prolonged period, and show effi-
cacy in reducing the growth of aggressive TNBCs in an orthotopic
mouse model. The data also indicate the critical importance of
dosing schedules for clinical trial consideration when evaluating
the therapeutic activity for amphiphilic polymers with pro-drug
functionality.
2. Results and Discussion
2.1. Polymer Pro-Drug Design, Synthesis, and Characterization in
2D Cell Culture
In this study we designed polymers around three guiding prin-
ciples; 1) ease of synthesis, 2) similarity to materials in exist-
ing clinical practice, and 3) accessible functionality to conjugate
a wide variety of therapeutic agents. We considered also some
secondary criteria, that is, that the chemistries should be suffi-
ciently flexible so that a single polymer backbone might serve in
future as a platform for multiple and/or combinations of drugs,
and that the construction might also encode for self-assembly
into nanoparticles suitable for systemic injection. Accordingly,
we synthesized the polymers by using poly(ethylene glycol), with
either methoxy and hydroxyl, or bis(hydroxyl), termini to ring
open lactide, and a protected amino-functional cyclic carbonate
derived from serinol, to provide a subsequent site for drug con-
jugation. In this way, we produced materials with poly(ethylene
glycol)-block poly(lactide) segments very similar to those of the
clinically-used Genexol formulation,[12] but with a third compo-
nent of a degradable polycarbonate with amine-functionality ac-
cessible following deprotection. The structures of the initial three
candidate polymers P1, P2, and P3 are shown in Figure 1A, and
the syntheses and primary characterization data (IR, NMR, GPC)
were as reported by us recently.[13] The polymers differed in terms
of the PEG chains used, with a methoxy-PEG2000 used to ini-
tiate lactide polymerization in P1, methoxy-PEG5000 in P2, and
PEG4000 with two terminal hydroxyl termini used in P3. The ef-
fects of these varying PEG components were to modify the self-
assembly properties, with changes in micellar-like nanoparticle
structure as the polymers ranged from AB-type blocks (P1, P2) to
BAB blocks (P3). Dropwise addition of these polymers from ace-
tone solution into excess deionized water resulted in the rapid
formation of nanoparticles, which were well-dispersed and col-
loidally stable in aqueous suspension owing to their negative zeta
potential and surface PEG layers (Figure 1B). Preliminary charac-
terization of their abilities to enter cells of interest in breast can-
cers (MCF7, HCC 70, MDA-MB-468, andMDA-MB-231 cells) in-
dicated internalization of Cy5-labelled polymers P1–P3within 4 h
in all cases (Figure 1C–F). In addition, the polymers were found
to be well-tolerated in the cell lines tested, based on metabolic
activity and membrane integrity assays (Figure S1, Supporting
Information)
Subsequent experiments measured the rate and extent of in-
ternalization in selected breast cancer and also healthy breast
cells. We also evaluated uptake in THP1 macrophages, as a
surrogate measure to indicate likelihood of nanoparticle clear-
ance from circulation, as this is known to occur via macrophage
involvement.[17] In most cases, the P2 formulation, with the
methoxyPEG5000 hydrophilic outer block and the smallest size
(<80 nm) was endocytozed most rapidly and to the greatest ex-
tent in the cancer cells (Figure 2). The size of nanoparticles
played a relevant role on the nanoparticle internalization, as P1
(>100 nm) presented the lowest uptake in the different cell lines.
We also observed some cell line specificity in nanoparticle in-
ternalization, as P2 and P3 entered MCF7, HCC70, MDA-MB-
231, and MDA-MB-468 cells at different rates, but were inter-
nalized at similar rates into THP1 derived macrophages. This
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Figure 1. In (A) is shown the synthetic route to candidate polymers, with the properties of nanoparticles P1–P3 formed outlined in (B). Plates C-F are
confocal micrographs indicating the relevant extent of internalization of P1 (left), P2 (middle), and P3 (right) in MCF7, HCC 70, MDA-MB-468, and
MDA-MB-231 breast cancer cells. Uptake of nanoparticles labelled with Cy5 at 50 µg mL−1 for 4h. Cy5 and Hoechst nuclei stain fluorescence shown in
magenta and blue, respectively. Bar represents 50 µM.
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Figure 2. A) Rate of uptake of polymer nanoparticles P1-P3 in selected normal breast (MCF-10a), macrophage (THP1), and breast cancer cells (MCF7,
HCC 70, MDA-MB-468, and MDA-MB-231). B) Further analysis of the internalization kinetics of P1–P3 (50 µg mL−1) in MCF7 cells, and C) MDA-MB-
231TNBC cells revealed an initial high rate of uptake (up to 1 h) followed by a slower period and near steady state at 4 h. D,E) The extent of nanoparticle
internalization (at 2 h) was concentration dependent in both D) MCF7 cells and E) MDA-MB-231 TNBC cells.
may have reflected the likely different PEG densities at the
surfaces.[18]
The mechanisms by which the polymers entered cells were
investigated by fluorescence microscopy, in assays wherein
nanoparticles were incubated with target cells (MCF7 breast can-
cer and MDA-MB-231 TNBC) at different temperatures and in
the presence or absence of specific (intra)cellular trafficking in-
hibitors (Figure 3). In these experiments, concentrations were
carefully chosen to ensure that all inhibitors were used at con-
centrations well below toxicity thresholds (Figure S2, Supporting
Information, ESI), as prior reports have shown marked effects of
certain inhibitors on both metabolic activity and viability of sev-
eral cancer cell lines.[19]
These data indicated that polymer nanoparticle internaliza-
tion was energy-dependent in both the MCF7 breast cancer
cell line and in MDA-MB-231 TNBC cells, as evidenced by the
significantly reduced uptake at 4 °C compared to 37 °C (Fig-
ure 3B,C). Furthermore, co-localization studies demonstrated
that there was some lysosomal accumulation following internal-
ization (Figure 3A). Taken together these data indicate receptor-
mediated endocytosis and subsequent trafficking to lysosomes as
a potential uptake pathway. It should be noted that the internal-
ization routes were not expected to be mediated by specific re-
ceptors, as the polymers were not decorated with any ligands to
engage cell surface receptors, however, chlorpromazine signifi-
cantly reduced uptake of P1–P3 compared to cells not treatedwith
the inhibitor (Figure 3D). These results showed that clathrin-
mediated pathways were involved in the internalization of the
polymers. Furthermore, genistein significantly reduced the in-
ternalization of P2 and P3, indicating that these nanoparticles
also exploit caveolin-mediated routes of endocytosis (Figure 3E).
Interestingly, P1 internalization was not affected by genistein,
suggesting that these larger particles (115.8 ± 7.5 nm) are not
uptaken via the caveolin-mediated routes. This finding may ex-
plain the reduced levels of cellular internalization of P1 com-
pared to P2 and P3 that were observed (Figure 2). Inhibition of dy-
namine with dynasore resulted in significantly reducing uptake
levels of all particles (Figure 3F), supporting the involvement of
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Figure 3. Internalization of polymers in selected cell lines. The influence of temperature on P1-P3 nanoparticle uptake in A) MDA-MB-231 and B) MCF7
cells, and C–F) the effect of endocytotic inhibitors on internalization; C) chlorpromazine (CPZ), D) genistein, E) dynasore, and F) nocodazole. Data
represent mean ± SD (n = 3). The group in the presence of NPs but without inhibitor treatment was used as the control groups, and their uptake was
expressed as 100%. Statistical significance was determined between control and treated groups by one-way ANOVA followed by Sidak’s post hoc test
for multiple comparisons (*p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001). Live cell fluorescence microscopy G) of Cy5-labelled P2 nanoparticles
co-localization with lysosomes in MDA-MB-231 TNBC cells. Cells were exposed to nanoparticles for 60 min. Cell lysosomes (green) are stained with
LysoTracker Green and nuclei with Hoechst 33 342 (blue). Cy5 signal has been colored red to aid visulization of co-localization with green lysosomal
signal. The co-localization is indicated in merged panels (yellow) and with white arrows. Two independent repeats are shown from a total of four repeats
conducted. Scale bar is 25 µm.
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Figure 4. Representative ex vivo images at A–C) 1, 4, 6, and 24 h post-injection and quantitation of ex vivo organ data at D) 1h, E) 4h, F) 6h, and
G) 24 h, to allow comparison between Cy5-labelled NPs, highlighting the fluorescence signal in organs important for nanoparticle clearance from the
bloodstream as a percentage of the total fluorescence in all organs (n = 2) (Br: brain, H: heart, Lu: lungs, Li: liver, P: pancreas, Sp: spleen, K: kidneys,
LN: lymph nodes, U: urine, Bl: bladder) of A) P1, B) P2, and C) P3. In (H–J) are shown in vivo images of mice treated with Cy5-labelled H) P1, I) P2, and
J) P3.
the dynamin-dependent caveolin- and/or clathrin-mediated path-
ways. Finally, inhibition of microtubule transport with nocoda-
zole demonstrated no significant effect on P1–P3 internalization.
In no cases was complete inhibition of internalization demon-
strated, showing that uptake likely took place by multiple and
simultaneous routes, again in accord with prior assays of non-
targeted nanoparticles.[19,20]
2.2. Tolerability and Biodistribution Studies
We next moved to preliminary experiments to evaluate the pri-
mary tolerability and biodistribution of the polymers in healthy
mice. Hemocompatibility assays with human blood showed that
P2 and its Cy5 variant were not hemolytic below 30 µg mL−1 and
slightly hemolytic at 300 µg mL−1, (Figure S3, Supporting Infor-
mation, ESI). The three Cy5-labelled formulations were then in-
jected via tail vein and the organs were imaged after specific time
points (Figure 4).
As apparent from the images of themice during the assays and
also of ex vivo isolated organs, the polymers all accumulated in
the liver, with P3 showing the highest levels of hepatic uptake at
all time-points. No adverse effects were noted in themice over the
time periods in the assays, indicating that the formulations were
well tolerated at the concentrations used (500 µg mL−1). When
considered in conjunction with the cell internalization data, in
which the P2 formulation was the most rapidly internalized, and
to the greatest extent, of all the polymers, we decided to focus fur-
ther on this polymer. In addition, the prior data had shown that
P2 nanoparticles were processed to lysosomal compartments and
thusmight be subjected to degradative pathways which would re-
sult in intracellular drug release.
2.3. Evaluation of Polymer-Doxorubicin Pro-Drug Penetration
and Efficacy in 2D and 3D Cultures
We therefore modified the P2 formulation to carry the well-
established cytotoxic drug, doxorubicin, with the chemistries de-
signed such that doxorubicin was conjugated to the polymer
backbone via a urea linkage. This linker was chosen in order
that the drug should be retained on the polymer during transit
in the body, and be more resistant to metabolism in the liver,
while being susceptible to proteolytic enzymes overexpressed in
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breast cancers which were previously shown to release urea pro-
drugs.[16] Previous studies[21] had shown that the doxorubicin
urea linker to the polycarbonate backbone was stable at pH 7.4,
but that the drug released over time at acidic pH 5.0, and thus
we considered the chemistries to be suitable in the first instance
for our investigation. NMR analysis indicated that the polymer
prodrug, denoted as P4, contained ≈10 molecules of doxorubicin
per chain indicating a coupling yield of ≈80% based on the 12–
13 free NH2 units available per chain following BOC deprotec-
tion. The final weight percentage of doxorubicin in the polymeric
prodrug system varied by less than 10% when measured by two
spectroscopic techniques (e.g., for 10 units 18%w/w byNMR and
12% byUV–vis). When formed into nanoparticles P4 was slightly
larger (130 nm) than its precursor P2 (≈80nm), and thus in the
first instance, imaging flow cytometry was used to evaluate the
internalization of P4 compared to P2 as analogues with differ-
ent size but the same outer chemical functionality. In addition, it
was of interest to characterize further the cellular uptake of P2-
Cy5 nanoparticles in relevant breast cancer cells, as we observed
that the rate of cell uptake was dependent on the cell type (Fig-
ure 2A). MCF7 and MDA-MB-231 presented similar extents of
nanoparticle internalization, with the majority of cells showing
higher Cy5 fluorescence in their interior compared to the fluo-
rescence within the cell membrane area (Figure 5A,B). As cor-
roborated by our previous finding (Figure 2A), MCF7 presented
higher nanoparticle uptake than MDA-MB-231 (Figure 5G), but
the former had lower nuclei colocalization than the latter within
4 h incubation time (Figure 5H). When comparing the intracel-
lular distribution of doxorubicin following MDA-MB-231 expo-
sure to P4 nanoparticles and free drug for 48 h, the free drug
was found to have reached the nuclei of the entire cell popula-
tion, whereas <31% of cells treated with polymer nanoparticles
showed evidence of doxorubicin in cell nuclei as apparent from
fluorescence colocalization (Figure 5O).
The P4 polymer-doxorubicin pro-drug was then imaged in
more detail in MDA-MB-231 cells by confocal microscopy and
tested for efficacy in both 2D and 3D cell culture settings. For
these assays, doxorubicin and P4 were dosed at 1 µM equivalent
doxorubicin concentration.
The cell-based assays indicated that in 2D culture (Figure 6
and Figure S4, Supporting Information), free doxorubicin was
visible in the nuclei of MDA-MB-231 cells within 4 h, while
the P4 pro-drug showed preferential accumulation in the cyto-
plasm (Figure 6A,C and in accordance with Figure 5I–O). How-
ever, in the 3D cultures, fluorescence from doxorubicin was ap-
parent throughout the spheroids when P4 was administered,
whereas for free doxorubicin, the fluorescent signals were con-
centrated in the outer layers only (Figure 6B,D). These data
demonstrated that P4 either penetrated throughout the ≈500 µm
depth of the spheroids as an intact polymer pro-drug, perhaps
by multiple transcytosis pathways, and/or that gradual release
of doxorubicin took place as the polymer formulation trafficked
through the 3D mass. In contrast, the localization of doxoru-
bicin in the spheroid periphery when added as a free drug, was
indicative that passive transport of the drug through the 3D struc-
ture was slow and less efficient than that of the P4 polymer
formulation.[22] Extensive washing of the spheroids before and
after incubation with the polymers and free doxorubicin was
carried out to ensure that any loosely-associated cells were re-
moved, and thus to discount any confounding data from for-
mulations transporting into partly disaggregated cell layers or
disrupted spheroids. Comparison of IC50 values in the MDA-
MB-231 cells in 2D culture suggested little difference in po-
tency between the polymer pro-drug and doxorubicin (Figure 6E)
but, intriguingly, there were differences in the volumes of the
3D spheroids between free drug and P4 at higher concentra-
tions tested (Figure 6F). At the highest concentration (10 µM),
there was an observed reduction in the spheroid volume of
≈41% and 56% (Figure S5, Supporting Information) for free dox-
orubicin and P4 respectively compared with pre-treatment vol-
umes. In addition, it was notable that at some lower concen-
trations (1 and 0.1 µM) of doxorubicin equivalent, the P4 for-
mulation was markedly more effective in reducing spheroid vol-
ume than doxorubicin alone, which again may reflect different
penetration of drug and polymer into the 3D spheroids. For ex-
ample, the disruption of internal regions by P4 may have led
to a greater loss in spheroid integrity, and hence volume, com-
pared to damage to the outermost layers by the free drug. How-
ever, it should be noted that spheroid volume is an indirect
measure of cytotoxic efficacy in these assays, especially as the
spheroids were cultured as tightly-associated cell aggregates, and
thus it was perhaps not too surprising that polymer and free
drug had similar effects on the spheroid volume at this time
point.
2.4. Efficacy Studies of Polymer Doxorubicin Pro-Drug in an
Orthotopic Triple Negative Breast Cancer Mouse Model
Since in our case the main interest in these experiments was
whether the P4 formulation could penetrate beyond a cell mono-
layer, we accordingly moved to in vivo assays, in which efficacy
was evaluated in an orthotopic mouse model of MDA-MB-231
TNBC. It is well-established that such models are complex to es-
tablish and the tumors are difficult to treat,[23] thus while cog-
nizant of the obvious differences in mouse tumors and human
TNBC, we considered this model as an appropriate pre-clinical
assay for the P4 formulation.
Tumors were formed in mice following injection of biolumi-
nescent MDA-MB-231 fLuc cells into mammary fatpads, with a
subsequent growth period of 21 days. Established tumors were
confirmed by palpation, and mice were dosed according to two
different schedules to take into account the expected longer circu-
lation time of the P4 carrier compared to doxorubicin. The mice
were dosed either 3 times in the first week, and then once per
week for the next 2 weeks, at doxorubicin (or equivalent) con-
centrations of 2 mg kg−1, or 3 times per week for 2 weeks at a
doxorubicin concentration (as free drug or as dosed equivalent)
of 4 mg kg−1. In all cases, saline was used as the vehicle control.
The experimental schedule included observation of the mice for
a further 2 weeks following the treatment period, and monitor-
ing of the health of each mouse via measurements of body mass
throughout the assays. The location of Cy5-labelled P4 formu-
lations in the mice following injection was determined by IVIS
imaging, and the bioluminescence of theMDA-MB-231 fLuc cells
was used as ameasure of tumor size, with reduced luminescence
taken as an indicator of tumor regression. The data from the in
vivo assays are shown in Figure 7.
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Figure 5. Synthesis of P4 (top) and characterization of cellular trafficking of A–H) P2-Cy5 and I–O) P4 via imaging flow cytometry. Left images show the
cell masks used to determine the ratio of nanoparticle internalization in A) MDA-MB-231 and B) MCF7 cells. Histograms of Cy5 fluorescence intensity
with cell images of correspondent intensities in C) MDA-MB-231 and D) MCF7. Histograms of bright detail fluorescence intensity with top images
representing the majority of cells with homogenous uptake and bottom image illustrating cells with nanoparticle accumulation in larger vesicles in
E) MDA-MB-231 and F) MCF7. Fluorescence intensity and bright detail fluorescence intensity values of G) MDA-MB-231 and MCF7. H) Nanoparti-
cle nuclei colocalization in both MCF7 and MDA-MB-231. P2-Cy5 nanoparticles were incubated with MDA-MB-231 and MCF7 at 50 µg mL−1 for 4 h
(n = 3). Images on the right show histograms of the ratio of nuclei colocalization of I) P4 and J) the free drug in MDA-MB-231 cells. Pictures illustrating
different ratios of nuclei colocalization of K) the nanoparticle and L) the free drug. Histograms of doxorubicin fluorescence intensity of cells exposed
to M) the nanoparticle and to N) the free drug. O) Comparison of doxorubicin fluorescence intensity and nuclear colocalization between MDA-MB-231
cells exposed to P4 and free drug. MDA-MB-231 cells were incubated with 1 µM doxorubicin (23 µg mL−1 nanoparticles) for 48 h. Data was acquired in
a ImageStream Flow Cytometer and analyzed using IDEAS software (v. 6.2, Amnis).
The initial imaging results (Figure 7A) provided evidence that
the polymer pro-drug P4 was retained in the bodies of the tumor-
bearingmice for prolonged periods, as fluorescence from the Cy5
label on the polymer was visible 24 h after injection (Figure 7A).
Since the heart is an organ of concern in cancer therapies due to
the dose-limiting cardiotoxicity of free doxorubicin, wemeasured
the fluorescence of excized heart as well as tumors and spleens.
Images of these organs (Figure 7B) exhibited Cy5 fluorescence
after 24 h, with enhanced accumulation of the polymer formu-
lation in the tumors and spleens compared to the heart. These
data were estimated from the luminescence intensities and in-
dicated that tumor accumulation was 17-fold higher than in the
heart (radiance values of ≈9.6 × 108 p s−1 cm−² sr−1 in the tu-
mors compared to ≈5.7 × 107 p s−1 cm−² sr−1). For mice treated
with 2 mg kg−1 equivalent of doxorubicin using 5 doses over
3 weeks the data indicated some differences between the poly-
mer pro-drug P4 and free doxorubicin at individual time-points.
Examination of the bioluminescence from the MDA-MB-231
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Figure 6. Confocal microscopy of MDA-MB-231 cells treated with P4 polymer-doxorubicin pro-drug nanoparticles in A) 2D culture and B) spheroids
compared to free doxorubicin in C) 2D and in D) 3D. Cells were exposed to P4 and free drug for 4/24/48 h (2D) and 48 h (3D) at 1 µM doxorubicin
(23 µg mL−1 nanoparticles). 3D spheroids images are 5 µm stacks (B/D). Scale bars represent 200 µm (B/D) and 50 µm (A/C). In the micrographs, the
Hoechst nuclear stain is depicted in blue, with the fluorescence of doxorubicin false-colored yellow. IC50 values for P4 compared to doxorubicin in 2D
are shown in (E), while (F) indicates volume changes of spheroids following dosing with P4 and doxorubicin respectively.
fLuc cells shows that tumors were well-established (Figure 7C–
E, left-hand side) at the start of the study, but that there was
considerable variation in the sizes of the tumors across the an-
imals. Following treatment (Figure 7C–E, right-hand side), it
was apparent that most of the tumors had grown, but there was
still considerable heterogeneity in the bioluminescence recorded.
Quantification of the data (Figure 7F) indicated that the P4 for-
mulation was slightly more effective than the free drug at the
38 day time-point, but in terms of cumulative efficacy there
were no significant differences. However, no serious adverse ef-
fects on the mice overall were detected in terms of overall body
weight for the animals which received treatment with the poly-
mer formulations (Figure 7G), and the P4 formulation was bet-
ter tolerated. These data are thus in accord with prior studies
indicating that some delivery systems for doxorubicin improve
tolerability of chemotherapy but not overall efficacy.[24] For the
study in which the mice were treated more frequently, but over
a shorter period and at a higher dose (4 mg kg−1), there was
no difference in ability to retard tumor growth for free doxoru-
bicin compared to P4 (Figure S6, Supporting Information), but
both treatment groups showed efficacy as expected against ve-
hicle control. In addition, data from H+E staining of tumors
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Figure 7. Fluorescence images of Cy5-labelled P4 nanoparticles captured 24 h after injection into MDA-MB-231 tumor-bearing mice A) in vivo and B)
ex vivo with organs (H: heart, Sp: spleen, T: tumor). In (C–E) are shown luminescence images of MDA-MB-231 fLuc tumor-bearing mice at day 17
(pre-treatment) and prior to termination (day 45) for the treatment groups C), P4, D) free doxorubicin, and E) vehicle control (saline) following dosing
with 2 mg kg−1 equivalent of doxorubicin using 5 doses over 3 weeks. In (F) are shown tumor volumes as measured by bioluminescence intensities of
MDA-MB-231 fLuc following dosing with 2 mg kg−1 equivalent of doxorubicin using 5 doses over 3 weeks. The dotted lines indicate the dosing period.
In (G) are shown body weight changes of MDA-MB-231 tumor-bearing mice during treatment (10 animals per group). Free doxorubicin and P4 were
dosed with 2 mg kg−1 equivalent of doxorubicin using 5 doses over 3 weeks as described for data in (C–F). Data expressed as mean ± SD.
recovered at the end of the treatment period (Figure S7, Sup-
porting Information) showed no difference between P4 and free
drug, suggesting that at the higher and more frequent dosing,
there was no advantage to using the polymer formulation. From
the histological analysis, the distribution of H+E positive cells
was not significantly altered for mice treated with free doxoru-
bicin compared to P4. It might be expected that the nanopar-
ticle formulation might not transport away from the blood ves-
sels as easily as free doxorubicin, but from H+E stains alone it
was not possible to determine whether the penetration of free
drug and P4 into the tumors was the same, or whether P4 had
penetrated further but released doxorubicin less efficiently in
the tumors as compared to release in the prior 3D spheroid
experiments.
When considered as a whole, the data are revealing, as they in-
dicate marked differences between the performance of the poly-
mer formulation in the 3D spheroids and in vivo. There have
been many discussions on the limits of tissue models, and in-
deed pre-clinical animal models, and their relevance for transla-
tion to human clinical performance.[25] However, recent papers
have indicated some successes in using advanced 3D cancer
spheroids for screening cancer drug formulations,[26] and our
data showed that in the 3D cultures, the P4 formulation trans-
ported well through the densely packed cell layers. In addition,
it has been very recently shown that transcytosis is an impor-
tant pathway for nanoparticle transport in tumors.[27] Therefore,
it is possible to speculate that the efficacy of the P4 formulation
compared to the free drug in the dense compacted spheroidsmay
be partly accounted for by multiple transcytosis events. However,
the lack of any significant efficacy difference in vivo between the
P4 doxorubicin polymer pro-drug and doxorubicin itself is less
easy to attribute to intercellular transport differences. The P4 for-
mulation contained a urea linkage, and thus while cytotoxicity
was observed with the polymer pro-drug, the rate or location of
release of doxorubicin within the tumor regions may not have
been any different to that of the free drug itself. It should be
noted that the polymers used in this study were deliberately not
“targeted”, as in order to maintain as simple a formulation as
possible for potential translation, we did not attach any ligands
to the polymers which might have aided internalization in spe-
cific regions of the tumor. Thus we were reliant on the inherent
passive accumulation of the polymers in the tumors, and with-
out detailed analysis of the individual tumors in the mice, it is
not possible to indicate whether vasculature may have been dis-
rupted or any EPR effect might take place in these regions. The
EPR phenomenon has been widely discussed in the context of
cancer biology in both pre-clinical and human studies,[28] but is
not a feature of all cancers and is highly tumor-dependent. The
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H+E data did not show marked differences between areas of the
tumor for mice treated with doxorubicin and the polymer formu-
lation P4. However, without in depth cell and tissue analysis to
ascertain at what rate doxorubicin reached the tumors or was re-
leased from the polymers in tissue we cannot identify clearly why
P4 was more effective in vitro compared to free drug but not in
vivo. Our future studies will address inmore detail if transcytosis
pathways or transport in tumor regions are the more dominant
factors in the efficacy of these and related polymers.
3. Conclusions
The experiments reported here have shown that a range of am-
phiphilic polymers, derived in simple steps from accessible pre-
cursors and with components similar to those used in clinically-
applied formulations, can be assembled into kinetically-trapped
micellar-like nanoparticles. These rapidly entered a range of
breast cancer cells by energy-dependent routes in 2D cell cul-
ture, and were found to be well-tolerated and with no identifi-
able adverse effects when injected systemically in mice. A side-
chain derivatized polymer pro-drug variant, with doxorubicin
attached by a urea linker, was shown to bemore effective in pene-
trating through dense-packed spheroids of TNBC MDA-MB-231
cells than free doxorubicin. Although the polymer pro-drug dis-
played enhanced therapeutic potential in the spheroids, it was
not significantly more potent in reducing tumor volume in an ag-
gressive orthotopic MDA-MB-231 tumors in mice. However, no
weight loss was observed in the mice following administration
of the polymer-doxorubicin conjugate, suggesting that future
studies might focus on changes in dosing schedules to maxi-
mize therapeutic window, as is applied clinically for current li-
posomal doxorubicin formulations. We believe these “first gen-
eration” materials, which are biodegradable and similar to those
used in current human cancer therapies, but which have the ad-
vantage of additional functional groups allowing attachment of
combination drugs and targeting ligands, might advantageously
be developed further for cancer therapies.
4. Experimental Section
Materials: Standard reagents, solvents monomers and other materi-
als for chemical synthesis were purchased from ThermoFisher or Sigma-
Aldrich and used without further purtification. HuMEC basal serum free
medium (cat. # 12653-018), bovine pituitary extractmedium (cat. # 13028-
014), HuMEC supplement kit (cat. # 12754-016), and high glucose DMEM
(phenol red free, cat. # 31053-028) were acquired from Gibco (Life tech-
nologies). High glucose DMEM (cat. # D6546), RPMI-1640medium (phe-
nol red free cat. # R7509 and with phenol red cat. # R0883), Trypsin–EDTA
(cat.# T3924), TOX7 LDH kit (cat. # 1 002 455 517), Phorbol 12-myristate
13-acetate (PMA, cat.# P8139), foetal bovine serum (FBS, cat.# F7524),
penicillin-streptomycin antibiotic solution (10 000 U penicillin and 10 mg
mL−1 streptomycin, cat. # P0781), l-glutamine (200 mm, cat. # G7513),
and DMSO (cat.# D2438) were purchased from Sigma-Aldrich. Hoechst
33 342 (cat.# H1399) and Presto Blue 10x solution (cat. # A13262 100mL)
were acquired from Invitrogen.
Polymer Synthesis: Polymers P1–P3 were synthesized as reported
previously,[13] using methoxypoly(ethyleneglycol) (MeO-PEG) of approx-
imate molar masses of 2000 Da and 5000 Da, and a dihydroxyPEG
of approximate molar mass of 4000 Da to ring-open lactide and a
BOC-protected cyclic carbonate monomer derived from serinol. Accord-
ingly, a predetermined amount of PEGylated chain initiator (mPEG2000,
mPEG5000, or PEG4000,), lactide, and the BOC-protected cyclic carbonate
were added to a pre-dried glass vial and capped. In order to maintain a
constant length of hydrophobic chains for each PEGylated chain initia-
tors, [M]/[I] was adjusted accordingly. Dry dichloromethane (5–10 mL),
was added at room temperature, followed by 1,8-diazabicyclo[5.4. 0]undec-
7-ene (DBU, 2–3%mol/mol compared to the total amount of monomers)
which was dissolved in extra dichloromethane (1 mL) and added to cat-
alyze the polymerization. After the reaction was complete, the catalyst was
deactivated and the polymers were purified via multiple solvation and pre-
cipitation steps from dichloromethane into hexane and dried in vacuum.
Typical yields for conversion of monomer to polymer were 75–80% w/w.
Labelling of Polymers with Cy5: The same reaction conditions were
used for polymers P1–P3 to conjugate an amine-functional Cy5 to the
hydroxyl-terminus of the polymers via disuccinimidyl carbonate (DSC)
coupling. A sample of polymer (100 mg), triethylamine (TEA, excess;
10 µL) in dry MeCN (0.5 mL) and DSC (excess; 5 mg) in dry MeCN (1 mL)
was added to a dry glass vial under continuous stirring at 0 °C and left for 3
h. A stock solution of Cy5-amine and TEA was prepared in dry MeCN, with
Cy5 at 1% wt/wt to the polymer and the TEA concentration in excess with
respect to the dye. Henceforth, 1 mg Cy5 and 10 µL TEA were dissolved
in 2 mL dry MeCN. This was then added to the reaction under constant
stirring at 0 °C and left for a further 3 h. Subsequently, the resultant con-
jugated polymer was purified through multiple precipitation steps in cold
hexane:diethyl ether (3:5 v/v) and left to dry in a vacuum oven to yield
Cy5-conjugated polymer. The Cy5 content in the mixed micelles was cali-
brated against Cy5-amine standards (𝜆exc = 647 nm, 𝜆em = 665 nm) using
fluorescence, based on a published procedure.[21]
BOC Deprotection: A predetermined amount of PEGylated copolymer
was dissolved in extra dry dichloromethane (3 mL). The optimum amount
of trifluoroacetic acid was found to be 5 eq with respect to the calculated
tBSC units and was added slowly to the polymer mixture at 0 °C. The re-
action mixture was left stirring for 20 min, and following precipitation in
cold hexane, was washed with cold diethyl ether and analyzed by 1H NMR
after complete drying. 1H NMR (t = 0 min) (400 MHz, DMSO-d6) 𝛿 =
5.26–5.10 (m, 80H), 4.17–4.01 (m, 168H), 3.52 (s, 492H), 1.48 (s, 240H),
1.39 (s, 370H). 1H NMR (after 20 min and post purification and drying)
(400 MHz, DMSO-d6) 𝛿 = 8.42 (bs, 30H), 7.18–7.02 (m, 34H), (≈10 units
deprotected) 5.24–5.11 (m, 62H), 3.51 (s, 492H), 1.55–1.41 (m, 204H),
1.38 (s, 320H).
Coupling of Doxorubicin to Polymer P2 to Form Polymer P4: N,N′-
disuccinimidyl carbonate (DSC) (1.5 eq. with respect to the amount of dox-
orubicin, 0.125 mmol, 32 mg) pre-dissolved in anhydrous MeCN (3 mL)
was added to a solution of doxorubicin (1.0 eq., 0.083 mmol, 48 mg)
in dry DMSO (3 mL) at 0 °C. Triethylamine (2.5 eq. with respect to
the amount of doxorubicin, 0.21 mmol, 30 µL) was added slowly to the
reaction mixture and left stirring for 4–5 h. Deprotected polymer P2; 1.0
eq., 0.083 mmol, 15 mg; equivalents were calculated to be in excess when
compared to each repeating carbonate backbone unit) was dissolved in
a mixture of anhydrous MeCN/ dry DMSO (50/50, v/v, 3 mL) and TEA
(2.0 eq. with respect to the amount of deprotected polymer, 0.166 mmol,
23 µL) was added, and the solution was subsequently added dropwise to
the previous reaction mixture. The reaction was left stirring for a further
3 h at 0 °C. The resultant drug-conjugated polymer was purified through
multiple precipitation steps in cold hexane:diethyl ether (1:5 v/v) mixture
and dialyzed against water:methanol (5:1 v/v) mixture for 24 h. Finally,
the purified aqueous suspension was freeze-dried for 48 h and stored at
−22 °C.
1H NMR (400 MHz, DMSO-d6) 𝛿 = 14.08 (s, 4H), 7.93 (d, J = 4.3 Hz,
8H), 7.69–7.65 (m, 4H), 7.63 (s, 4H), 7.07 (d, J = 7.1 Hz, 21H), 5.34 (d,
J = 8.7 Hz, 8H), 5.24–5.11 (m, 78H), 4.86 (d, J = 5.9 Hz, 4H), 4.61–4.56
(m, 4H), 4.50 (d, J = 10.1 Hz, 8H), 4.36 (d, J = 4.0 Hz, 12H), 4.16–3.93
(m, 205H), 3.81–3.74 (m, 8H), 3.71–3.66 (m, 4H), 3.51 (s, 492H), 3.24 (s,
4H), 3.07–3.01 (m, 8H), 2.94 (d, J = 5.9 Hz, 4H), 2.23 (d, J = 3.8 Hz, 4H),
1.50–1.41 (m, 200H), 1.38 (s, 290H).
Nanoparticle Preparation and Characterization: Kinetically-trapped
micellar-like polymer nanoparticles were prepared as described
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previously.[13] For all the polymers, a solvent–non-solvent precipita-
tion method was used to form nanoparticles, in which the polymers
(10 mg) were dissolved in acetone (1 mL) and added dropwise to
deionized water (10 mL, final concentration of 1 mg mL−1). Stirring at
550 rpm was maintained throughout the addition steps to allow stable
nanoparticle suspensions to form. The resultant suspensions were
stirred overnight at room temperature to ensure no solvent remained. All
nanoparticle suspensions were filter-sterilized (0.2 µm membrane) prior
to in vitro and in vivo studies.
Cell Culture: All cells were purchased from the American Type Culture
Collection (ATCC; Manassas, Virginia). MDA-MB-231, MCF7, MCF-10A,
HCC70, andMDA-MB-468 cells were used in a passage window of 15, and
RAW 264.7 cells in a passage window of 10. MDA-MB-231, MDA-MB-468,
HCC70, andMCF7 cells were cultured in DMEM (Sigma-Aldrich) and RAW
264.7 in RPMI (Sigma-Aldrich). Both media types were supplemented
with 10% (v/v) foetal bovine serum (FBS; Sigma-Aldrich) and 2 mm l-
glutamine (Sigma-Aldrich). THP1 monocytic cells were cultured in RPMI
medium supplemented with 10% FBS, 1% l-glutamine (200 mm), and
1% antibiotic solution (penicillin-streptomycin). THP1 cells were main-
tained with medium replacement by centrifugation and subcultured prior
to cell population reaching 106 cells mL−1. For differentiation, THP1 cells
(312 500 cells cm−2) were subcultured in appropriate dishes with antibi-
otic free medium supplemented with 100 ng mL−1 (162 nM) PMA for
2 days. MCF10a epithelial breast cell line was grown in HuMEC basal
serum free medium supplemented with bovine pituitary extract medium
and HuMEC supplement kit. Culture conditions were maintained at 37 °C
with 5% CO2 and 90% relative humidity.
In VitroNanoparticles Internalization Studies in Cancer Cells: Fluorometric-
Based Method: MCF7 and MDA-MB-231 breast cancer cells were plated
at 1 × 104 cells per well in 96 well plates and RAW 264.7 macrophages
seeded in 12 wells plates at a density of 1.2 × 105 per well. Following a 24
h culture period, culture medium was removed and Cy5-labelled nanopar-
ticles were applied in phenol red free medium containing 10% (v/v) FBS.
The time-dependence of cell uptake was assessed with 50 µg mL−1 so-
lutions of nanoparticles and at time points of 15, 30, 60, 120, 180, and
240 min. Additionally, the concentration-dependence of uptake was in-
vestigated at a fixed time point of 2 h with nanoparticle solution con-
centrations of 6.25–100 µg mL−1. Following exposure, nanoparticle so-
lutions were removed and cells washed three times with ice cold PBS.
Cells were then permeabilized with 1% (v/v) Triton X-100 solution applied
in PBS for 10 min at 37 °C. Permeabilized cells were thereafter pelleted
by centrifugation and nanoparticles quantified by fluorescent measure-
ment at 640/680 nm (𝜆ex/𝜆em). Quantification of nanoparticle uptake was
achieved via calibration curves of known nanoparticle concentrations di-
luted in 1% (v/v) Triton X-100 in PBS solution. Values were normalized to
viable cell number per well determined by the trypan blue exclusion test
and cell counting on a hemocytometer.
Flow Cytometry Assays for Assessment of Nanoparticle Internalization and
Transport: To characterize the rate of nanoparticle internalization, MCF7,
MCF10a, MDA-MB-231, MDA-MB-468, and HCC70 (31 250 cells cm−2)
and THP1 derived macrophages (312 500 cells cm−2) were incubated with
50 µg mL−1 P1/P2/P3-Cy5 for 15 min,30 min, 1 h, and4 h, then the cells
were thoroughly washed with PBS, preserved with 4% PFA in PBS, de-
tached using trypsin-EDTA and resuspended in 500 µL PBS. Fluorescence
was acquired under 488 nm excitation and 655–685 nm emission band-
width in a FC500 flow cytometer (Beckman Coulter). The median fluores-
cence intensity values of homogeneous and healthy cell populations was
used to quantify the cell uptake. To quantify nanoparticle internalization
rates in the different cell lines, the slope of the curve of regression analysis
of fluorescence intensity versus incubation time was normalized by each
nanoparticle fluorescence intensity (histograms can be found in Figure S8,
Supporting Information). Nanoparticle internalization and nuclei colocal-
ization was performed for P2-Cy5 (50 µg mL−1; 4 h incubation) in both
MCF7 andMDA-MB-231 cells and P4/free doxorubibin (1 µMdoxorubicin;
23 µg mL−1 nanoparticle; 48 h incubation) in MDA-MB-231 cells at 31250
cells cm−2. Following exposure to the different treatments, the cells were
incubated with Hoechst 33 342 at 2 µg mL−1 for 10 min. Then, they were
thoroughly washed with PBS, preserved with 4% PFA in PBS, detached us-
ing trypsin-EDTA, and resuspended in 50 µL PBS prior to acquiring the
images in an Image Streamx Mk II Imaging Flow Cytometer (Amnis) with
40x magnification. The data analysis was performed using IDEAS Image
Stream Analysis Software (Amnis). The imaging flow cytometry analysis
of nanoparticle internalization represents ratio of the intensity inside the
cell to the intensity of the entire cell and accounts for the preferential ac-
cumulation inside the cell compared to that in the cell membrane. The
cell uptake is represented by the total fluorescence intensity. The bright
detail is the intensity of localized bright spots within the masked area in
the image and a high value is related to the nanoparticle distribution into
larger vesicle-like structures rather than homogeneously distributed in the
cytoplasm.
Confocal Microscopy Imaging: Confocal microscopy analysis was car-
ried out in cells sub-cultured in glass dishes (CELLview culture dish,
Greiner Bio-One, Germany). MCF7, MDA-MB-231, MDA-MB-468, and
HCC70 (31 250 cells cm−2) and THP1 derived macrophages (312 500
cells/cm2) received P1/P2/P3-Cy5 at 50 µg mL−1 for 4 h and MDA-MB-
231 cells were treated for 4/24/48 h with P4/free doxorubicin (1 µM dox-
orubicin/23 µgmL−1 nanoparticle). In sequence, they were incubated with
Hoechst 33 342 at 5 µg mL−1 for 10 min, carefully washed with warm PBS
and preserved with 4% paraformaldehyde in sterile PBS. MDA-MB-231 3D
spheroids grown for 3 days were treated with P4/free doxorubicin (1 µM
doxorubicin/23 µgmL−1 nanoparticle) for 48 h. Then, they were incubated
with Hoechst 33 342 at 5 µg mL−1 for 10 min and were carefully washed
with warm PBS and preserved with 4% PFA in sterile PBS. The visualiza-
tion of intracellular probe accumulation was performed in a TCS SPE Leica
confocal microscope using 40x (2D cells) and 10x (3D spheroids) objec-
tives and the images were analyzed using ImageJ software.
Live Cell Fluorescence Microscopy: Cells were seeded in 96 well plates
at a density of 1 × 104 cells per well. Cells were incubated with 50 µg mL−1
Cy5-labelled nanoparticle solutions for 60 min. Cells were then stained
with Hoechst 33 342 (10 µg mL−1) and LysoTracker Green (50 nM) for
30 min and imaged on an inverted Nikon Eclipse TE 300 microscope on
DAPI, FITC, and Cy5 filters. Images were merged using ImageJ software.
Assessment of Internalization Mechanisms: To study the uptake mecha-
nisms of nanoparticles, chlorpromazine (CPZ; 30 µM), genistein (35 µM),
nocodazole (35 µM), and dynasore (20 µM) were applied to in-
hibit clathrin-mediated, caveolin-mediated, microtubule-mediated, and
dynamin-dependent endocytotic routes, respectively. Nanoparticle inter-
nalization was assessed via the fluorometric-based method (described
above) with the following amendments; cells were pre-incubated with in-
hibitors for 30 min, followed by application of nanoparticle solutions,
spiked with inhibitor, for 240 min.
Cytotoxicity Experiments: The PrestoBlue cell viability assay (Thermo
Fisher Scientific) and the lactate dehydrogenase (LDH) release assay
(Sigma Aldrich, TOX7 kit) were performed to assess nanoparticle cytotox-
icity. All cell types, but THP1 (see cell culture section above), were seeded
at 1 × 104 cells per well in 96 well plates and cultured for 24 h prior to as-
saying. Nanoparticles were exposed to cells for 48 h and applied in 100 µL
phenol red free DMEM containing 10% (v/v) FBS and 2 mm l-glutamine.
Triton X-100 applied at 1% (v/v) in phenol red free DMEM was used as a
cell death (positive) control and a vehicle control containing no nanoparti-
cles used as a negative control. Following exposure, 50 µL of supernatant
was collected per well for analysis of LDH content. Cells were washed twice
with warm PBS and 100 µL 10% (v/v) PrestoBlue reagent diluted in phe-
nol red free medium applied per well for 60 min at 37 °C. The resulting
fluorescence was measured at 560/600 nm (𝜆ex/𝜆em). Relative metabolic
activity was calculated by setting values from the negative control as 100%
and positive control values as 0% metabolic activity. Assessment of LDH
release was performed according to the manufacturer’s instructions and
involved adding 100 µL LDH detection reagent to the collected super-
natant samples and incubating at room temperature shielded from light
for 25 min. Absorbance was measured at 492 nm. Relative LDH release
was calculated with the negative control absorbance at 492 nm taken as
0%, and the positive control, assumed to cause total cell lysis, as 100%.
Hemolysis: The nanoparticle hemolysis assay was performed accord-
ing to a standard method for nanoparticle hemocompatibility.[29] Briefly,
fresh human blood was mixed to anticoagulant (1:10, citrate buffer:blood)
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and the hemoglobin content in blood was determined. The assay was per-
formed at standard 10 mg mL−1 hemoglobin concentration. Triton-X-100
(10mgmL−1, positive control), DPBS (negative control), PBS (vehicle con-
trol), and nanoparticles at 3; 30 and 300 µg mL−1 were incubated for 3 h at
37 °C with gentle mixing every 30 min. The percent hemolysis induced by
a test sample can be classified as non-hemolytic if lower than 2%, slightly
hemolytic within 2–5% and hemolytic if higher than 5%.[30]
3D Spheroid Assays: For doxorubicin and P4 confocal microscopy as-
says, MDA-MB-231 spheroids were prepared by the hanging dropmethod,
in which 5000 cells were cultivated for 3 days prior to receiving the ap-
propriate treatment. In the imaging assays, MDA-MB-231 spheroids were
treated after 3 days with P4/free doxorubicin (1 µM doxorubicin/23 µg
mL−1 nanoparticle) for 48 h, incubated with Hoechst 33 342 at 5 µg mL−1
for 10 min, and washed with warm PBS and preserved with 4% PFA in
sterile PBS prior to imaging with a TCS SPE Leica confocal microscope.
For the cytotoxicity assays, corning 7007 ultra-low attachment (ULA) 96-
well round bottom plates were used to culture the 3D spheroids. MDA-
MB-231 monolayer cells at 80% confluence were detached, collected, and
their number determined using a Biorad TC20 automated cell counter. Cell
suspensions were diluted in culture medium with the addition of Cultrex
basement membrane extract (Cultrex-BME, 100 µg mL−1) and cells were
seeded at 1000 cells per well to generate spheroids (final volume of cell
suspension in each well was 100 µL). The plates were centrifuged at 300
RCF for 5 min and cultured for 3 days until spheroid formation was con-
firmed by visual inspection. For dosing, doxorubicin and P4 were prepared
as solutions in media and added (100 µL) at concentrations of 1 µM (dox-
orubicin) and 1 µM equivalent doxorubicin (23 µg mL−1 P4 nanoparticles)
to wells containing a single spheroid in 100 µL of medium (making the to-
tal volume 200 µL). The plates were imaged, then incubated for 72 h with
images taken every day for 3 subsequent days. Spheroid volume analysis,
from images obtained with a Nikon Ti Eclipse inverted microscope, uti-
lized an open source macro for the FiJi distribution of ImageJ written by
Ivanov.[31] The measured area (S) from the macro data of a 2D projection





quently, the volume, (V = 4
3
𝜋r3) of an equivalent sphere.
The metabolic activity of cells from the spheroids was measured, as
a proxy of cell viability, after 72 h post treatment of the spheroids us-
ing an AlamarBlue Cell Viability assay. In these experiments, an aliquot
(100 µL) of cell culture medium was removed from each well and replaced
with 100 µL 10% (v/v) AlamarBlue reagent. The contents of the plate were
mixed vigorously for 5 min to destroy the spheroid structure, and the plate
was incubated for 4, prior to measurement of fluorescence using a Tecan
plate reader at an excitation/emission of 530–560/590 nm.
In Vivo Studies: In vivo biodistribution experiments were performed
in tumor naïve animals in order to assess distribution, organ accumula-
tion, and clearance of Cy5-labelled pHPMAs of different architectures. The
experiments were conducted under the UK Home Office Licence number
PPL P435A9CF8. LASA good practice guidelines, FELASA working group
on pain and distress guidelines and ARRIVE reporting guidelines were also
followed.
Eighteen 8–9 week old female immunodeficient CD-1 NuNu mice were
purchased from Charles River UK. Mice were maintained in individually
ventilated cages (Tecniplast UK) within a barriered unit, illuminated by flu-
orescent lights set to give a 12 h light–dark cycle (on 07.00, off 19.00), as
recommended in the guidelines to the Home Office Animals (Scientific
Procedures) Act 1986 (UK). The room was air-conditioned by a system de-
signed to maintain an air temperature range of 21 ± 2 °C and a humidity
of 55% ± 10%. Mice were housed in social groups, 3 per cage, during the
study, with irradiated bedding and autoclaved nesting materials and envi-
ronmental enrichment (Datesand UK). Sterile irradiated 5V5R rodent diet
(IPS Ltd, UK) and autoclaved water was offered ad libitum. The condition
of the animals was monitored throughout the study by an experienced an-
imal technician. After a week’s acclimatization, the mice were randomly
allocated by weight to the study groups of 6 mice per polymer type. As this
was a simple biodistribution study, no power calculation was required.
After warming the mice in a thermostatically controlled heating box
(Datesand UK), they were injected intravenously via the tail vein with
100 µL of a 500 µM solution of the selected polymer type in PBS. No ad-
verse effects were observed following the injections or for the duration
of the study. The concentration delivered was determined from a balance
of non-toxicity from in vitro analysis as well as sufficient fluorescent in-
tensity for imaging in vivo. Prior to the study time points, the mice were
anaesthetized with an injectable anesthetic combination (Anaestemine
[ketamine]/Sedastart [medetomadine], Animalcare Ltd. UK) before being
placed in the imaging system. Images were taken at 1, 4, and 24 h post-
injection, and two mice in each group were culled by cervical dislocation,
organs were dissected out and were imaged ex vivo at these time points,
with the other mice being allowed to recover from the anesthetic with ap-
propriate post procedural monitoring and therapy, including placing mice
on a heat pad and providing fluid replacement via wet mash once awake.
The organs excized and imaged were the kidneys, liver, spleen, pancreas,
lung, heart, bladder, brain, and lymph nodes (subiliac). A urine sample
(25 µL) was also collected and imaged.
For the orthotopic tumor assay, the following protocol was employed.
Sixty 6–7 week old female immunodeficient CD-1 NuNu mice were pur-
chased from Charles River UK and maintained as above. After a week’s
acclimatization, the mice were initiated with tumors as follows:
MDA-MB-231 fLuc cells with viability of >90% were re-suspended in
growth factor reduced matrigel at 2 × 106/100 µL and injected into the
left mammary fat pad just inferior to the nipple. Tumor establishment and
growth was monitored during the experiment by 2D optical imaging, car-
ried out under anesthesia in the IVIS Spectrum weekly, and were also mea-
sured by Vernier calipers (Camlab) twice weekly and animals were weighed
weekly. Dosing commenced on day 17 when the tumors had reached a
suitable size as established by caliper measurement and bioluminescent
imaging, average diameters around 6 mm.
Animals were randomized by volume and bioluminescence intensity,
with group numbers of 10 mice per group being arrived at by power calcu-
lations as described in the Supporting Information (Figure S9, Supporting
Information, ESI).
Injections for the efficacy study were carried out on days 1, 3, 5, 8, 10,
12 by the intravenous route. As above, a thermostatically controlled heat-
ing box (Datesand UK) was used to warm the mice, after which they were
injected via the tail vein with a solution (100 µL, 500 µM), of the selected
polymer in PBS. No adverse effects were observed following the injections
or for the duration of the study. Imaging was carried out weekly as follows:
The mice were anaesthetized with an injectable anesthetic combination
(Anaestemine [ketamine]/Sedastart [medetomadine], Animalcare Ltd. UK)
before being placed in the imaging system. At the pre-determined scien-
tific end point, animals were culled by cervical dislocation, tissues were
dissected out and were imaged ex vivo. The tissues excized and imaged
were the tumor, kidneys, liver, spleen, pancreas, lung, heart, bladder, brain,
and lymph nodes (subiliac). A urine sample (25 µL) was also collected
and imaged. In addition, the tumor, spleen, and heart were weighed prior
to preservation. All organs were preserved by snap freezing and fixation
(NBF) 50:50.
All images were collected using the IVIS spectrum imaging system,
PerkinElmer (MA, USA) and fluorescent signals were quantified using
regions of interest and quantified as photons emitted using Living Im-
age/Igor Pro Software (Caliper Life Sciences).
H&E Staining: Tumor sections were de-waxed twice in xylene and
rinsed twice in ethanol. The sections were then rinsed in tap water, incu-
bated with hematoxylin stain, and subsequently rinsed under tap water.
The sections were destained in acidified alcohol and rinsed in tap wa-
ter again. For the eosin staining, the sections were incubated in eosin
and rinsed in tap water, prior to dehydration in alcohol solutions and a
final cleaning stage in xylene. The glass coverslips were allowed to dry
overnight before recording of micrographs. The mean percentages of pos-
itively stained cells were recorded from 20 image fields of view taken at
random from the sections.
Statistical Analysis: Except where stated, otherwise, in the individual
experimental methods sections above, each in vitro experiment was per-
formed three times in triplicate. The statistical analyses of data were per-
formed using analysis of variance (one-way ANOVA) followed by Sidak’s
post hoc test for multiple comparisons, and the results were presented as
Adv. Therap. 2020, 2000103 © 2020 The Authors. Published by Wiley-VCH GmbH2000103 (13 of 15)
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the mean ± SD. Statistical significance was accepted at a level of p < 0.05.
(*p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001). GraphPad Prism
software (v7.03) was used for statistical analysis.
For the in vivo experiments, values obtained were analyzed using one-
way ANOVA followed by Dunnett’s test for multiple comparisons, and the
data presented as themean± SD. In all cases, differences were considered
significant when p*** < 0.001, p** < 0.01, and p* < 0.05.
Supporting Information
Supporting Information is available from the Wiley Online Library or from
the author.
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